NASDAQ · Biotechnology

CYTK (CYTK) Stock

$71.40 +0.69% NASDAQ: CYTK Healthcare

Valuation

MetricValue
Price$71.40
Market Cap$8.88B
P/E Ratio-10.98
P/B Ratio-60.30
P/S Ratio138.88
EPS (TTM)$0.00
52-Week High$88.31
52-Week Low$35.22
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE163.98%
ROA-46.45%
ROCE-40.42%
Gross Margin-695.45%
Operating Margin-695.45%
Net Margin-784.02%
Debt/Equity-7.32
Current Ratio4.54

Annual Financials (USD)

Metric20212022202320242025
Revenue$70.0M$95.0M$8.0M$18.0M$88.0M
Operating Profit$-186.0M$-324.0M$-496.0M$-536.0M$-612.0M
Net Profit$-215.0M$-389.0M$-526.0M$-590.0M$-785.0M
EPS$-2.80$-4.33$-5.45$-5.26$-6.54
Op Margin-264.5%-342.8%-6589.7%-2902.7%-695.4%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$841.0M$1.0B$824.0M$1.4B$1.4B
Total Liabilities$597.0M$1.1B$1.2B$1.5B$2.1B
Cash$113.0M$66.0M$113.0M$95.0M$123.0M
Borrowings$270.0M$750.0M$756.0M$789.0M$1.3B

Latest News

All You Need to Know About Cytokinetics (CYTK) Rating Upgrade to Buy Zacks · Jul 15, 2026 Wall Street Analysts Think Cytokinetics (CYTK) Could Surge 30.54%: Read This Before Placing a Bet Zacks · Jul 15, 2026 CYTK: Lowering target price to $86.00 Argus Research · Jul 15, 2026 What This Cytokinetics Insider Sale Might Mean With the Stock Up 110% Motley Fool · Jul 14, 2026 Cytokinetics Insider Sold Shares Worth $615,150, According to a Recent SEC Filing MT Newswires · Jul 14, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-143.0M$-300.0M$-414.0M$-396.0M$-510.0M
Investing Cash Flow$-197.0M$-273.0M$238.0M$-557.0M$-8.0M
Financing Cash Flow$8.0M$164.0M$58.0M$233.0M$-2.0M
Net Cash Flow$30.0M$-45.0M$46.0M$-18.0M$30.0M
Free Cash Flow$-191.0M$-311.0M$-416.0M$-400.0M$-535.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.33
EV / EBITDA-13.28
FCF Yield-5.89%
Quick Ratio6.66
Interest Coverage-5.64
Return 1Y93.01%
Return 3Y103.13%
Return 5Y137.98%

Ownership

Insiders Held0.67%
Institutions Held118.82%
Institutions Float Held119.62%
Institutional HolderSharesReport Date
T. Rowe Price Investment Management, Inc.17,523,8402026-03-31
Blackrock Inc.16,548,0112026-03-31
FMR, LLC10,723,1402026-03-31
Wellington Management Group, LLP8,009,4892026-03-31
Vanguard Portfolio Management LLC5,843,7822026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ABVXAbivax S.A. $136.94 +1.50% -24.37 $10.06B 0.00%
AXSM $202.83 +2.17% -52.94 $10.44B 0.00%
CORT $113.38 +0.03% 217.98 $12.26B 0.00%
CRSP $56.82 -0.28% -11.97 $5.48B 0.00%
HALO $107.72 +1.16% 23.58 $12.78B 0.00%

About CYTK

CYTK is led by CEO Robert I. Blum, employs 673 people, headquartered in South San Francisco, US, publicly traded since 2004.

CYTK stock trades at $71.40 with a market capitalization of $8.88B. The stock is valued at a price-to-earnings (P/E) ratio of -10.98, price-to-book of -60.30, price-to-sales of 138.88. Over the past 52 weeks the stock has ranged between $35.22 and $88.31, and currently trades 19.1% below its 52-week high.

On profitability, CYTK generates a return on equity (ROE) of 163.98% — well above the market average, a sign of a high-quality business, return on capital employed of -40.42%, an operating margin of -695.45%, a net profit margin of -784.02%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1159.93 +0.28% JNJ Drug Manufacturers - General $271.19 +2.01% ABBV Drug Manufacturers - General $259.99 +1.39% MRK Drug Manufacturers - General $149.94 +1.48% UNH Medical - Healthcare Plans $396.30 +1.77% NVS Drug Manufacturers - General $161.25 +6.04% AZN Drug Manufacturers - General $162.47 +0.21% AMGN Drug Manufacturers - General $438.12 +1.92% TMO Medical - Diagnostics & Research $600.50 -2.69% NVO Biotechnology $45.12 -0.46% ABT Medical - Devices $108.97 -1.26% GILD Drug Manufacturers - General $149.92 +2.45%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides